title: Management of cancer-associated disseminated intravascular coagulation.
abstract: Cancer may be complicated by the occurrence of disseminated intravascular coagulation (DIC). DIC is characterized by a widespread and intravascular activation of coagulation (leading to intravascular fibrin deposition) and simultaneous consumption of coagulation factors and platelets (potentially resulting in bleeding). Clinically, DIC in cancer has in general a less fulminant presentation than the types of DIC complicating sepsis and trauma. A more gradual, but also more chronic, systemic activation of coagulation can proceed subclinically. Eventually this process may lead to exhaustion of platelets and coagulation factors and bleeding (for example at the site of the tumor) may be the first clinical symptom indicating the presence of DIC. In some cases, the clinical presentation of DIC in cancer may be reminiscent of thrombotic microangiopathies, which is understandable in view of the role of endothelium in both conditions. The therapeutic cornerstone of DIC is treatment of the underlying disorder but supportive treatment, specifically aimed at the hemostatic system may be required.
authors.affiliation: Department of Medicine, Academic Medical Center, University of Ansterdam. Electronic address: m.m.levi@amc.uva.nl.
authors.forename: Marcel
authors.initials: M
authors.lastname: Levi
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D019468:Disease Management; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000150:complications* / Q000473:pathology; D057049:Thrombotic Microangiopathies / Q000097:blood / Q000150:complications / Q000473:pathology
chemical_list: D000925:Anticoagulants
keywords: Cancer; Coagulation; Disseminated intravascular coagulation; Fibrinolysis; Thrombotic microangiopathy; Tissue factor